Stem cell shot during bypass aims to rebuild failing hearts
Disease control
Recruiting now
This Phase 3 trial tests whether injecting lab-grown heart muscle cells (HiCM-188) into the heart during bypass surgery can help people with severe heart failure (NYHA class III-IV). Eighty participants will receive either the stem cells plus bypass or bypass alone. The main goal…
Phase: PHASE3 • Sponsor: HELP Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC